CoChat

β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis

Brophy, James M., Joseph, Lawrence, Rouleau, Jean L. · 2001 · Annals of Internal Medicine

The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.

Abstract

PURPOSE: Congestive heart failure is an important cause of patient morbidity and mortality. Although several randomized clinical trials have compared beta-blockers with placebo for treatment of congestive heart failure, a meta-analysis quantifying the effect on mortality and morbidity has not been performed recently. DATA SOURCES: The MEDLINE, Cochrane, and Web of Science electronic databases were searched from 1966 to July 2000. References were also identified from bibliographies of pertinent articles. STUDY SELECTION: All randomized clinical trials of beta-blockers versus placebo in chronic stable congestive heart failure were included. DATA EXTRACTION: A specified protocol was followed to extract data on patient characteristics, beta-blocker used, overall mortality, hospitalizations for congestive heart failure, and study quality. DATA SYNTHESIS: A hierarchical random-effects model was used to synthesize the results. A total of 22 trials involving 10 135 patients were identified. There were 624 deaths among 4862 patients randomly assigned to placebo and 444 deaths among 5273 patients assigned to beta-blocker therapy. In these groups, 754 and 540 patients, respectively, required hospitalization for congestive heart failure. The probability that beta-blocker therapy reduced total mortality and hospitalizations for congestive heart failure was almost 100%. The best estimates of these advantages are 3.8 lives saved and 4 fewer hospitalizations per 100 patients treated in the first year after therapy. The probability that these benefits are clinically significant (>2 lives saved or >2 fewer hospitalizations per 100 patients treated) is 99%. Both selective and nonselective agents produced these salutary effects. The results are robust to any reasonable publication bias. CONCLUSIONS: beta-Blocker therapy is associated with clinically meaningful reductions in mortality and morbidity in patients with stable congestive heart failure and should be routinely offered to all patients similar to those included in trials.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-134-7-200104030-00008

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 3

  1. Brophy JM, 1992, Can J Cardiol, 8, 495
  2. Packer M, 1993, Circulation, 88
  3. Avezum A, 1998, Can J Cardiol, 14, 1045

Cited by

See all 389

Metadata

Authors
Brophy, J. M., Joseph, L., & Rouleau, J. L.
Affiliations
Mount Sinai Hospital (CA)
Venue
Annals of Internal Medicine
Published
2001-04-03
Volume
134
Issue
7
Pages
550-560
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2023629207
Cited by
389
References
57
Citations by year
2026: 4 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 5 · 2019: 11 · 2018: 9 · 2017: 15 · 2016: 17 · 2015: 14 · 2014: 10 · 2013: 21 · 2012: 26
FWCI
18.61
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
beta-blockers, congestive heart failure, mortality, hospitalization, selective beta-blockers, non-selective beta-blockers, treatment efficacy, publication bias
MeSH terms
Adrenergic beta-Antagonists, Bayes Theorem, Heart Failure, Hospitalization, Humans, Research Design, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-134-7-200104030-00008
The paper
Brophy, J. M., Joseph, L., & Rouleau, J. L. (2001). β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-134-7-200104030-00008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.